Dillon & Associates
IBRX icon

Dillon & Associates’s ImmunityBio IBRX Stock Holding History

Dillon & Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$214K Hold
23,800
– – 0.03% 78
2026
Q2 		$214K Hold
23,800
– – 0.03% 78
2026
Q1 		$190K Sell
23,800
-2,000
-8% -$13.7K 0.03% 75
2025
Q4 		$52K Hold
25,800
– – 0.01% 77
2025
Q3 		$52K Hold
25,800
– – 0.01% 76
2025
Q2 		$77K Buy
+25,800
New +$69.4K 0.01% 77

Other funds holding IBRX

Kercheville Advisors
Kercheville Advisors San Antonio, Texas $361M AUM 57.53% 1-Year Est. Return
D.A. Davidson & Co
D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return
Sheets Smith Wealth Management
Sheets Smith Wealth Management Winston-Salem, North Carolina $958M AUM 21.88% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Doliver Advisors
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Dillon & Associates's IBRX Position: Q3 2026 in Review

Dillon & Associates held its ImmunityBio (IBRX) position steady in Q3 2026 at 23,800 shares worth $214K. The position accounts for 0.03% of the portfolio, ranked #78.

Dillon & Associates first reported a position in IBRX in Q2 2025 and has held it in 6 quarters since. 123 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Dillon & Associates held 23,800 shares of ImmunityBio worth $214K as of Q3 2026.
  • Dillon & Associates left its ImmunityBio share count unchanged in Q3 2026.
  • ImmunityBio made up 0.03% of Dillon & Associates's portfolio in Q3 2026, its #78 holding.
  • Dillon & Associates first reported a position in ImmunityBio in Q2 2025 and has held it in 6 quarters since.
  • 123 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Dillon & Associates's 13F filing for Q3 2026, filed 22 Oct 2026.